Abstract
This work is aimed at conducting a pharmacoeconomical analysis of chemotherapy for small cell lung cancer using ABC/ VEN analysis to identify the most expensive chemotherapy regimens. A retrospective evaluation of chemotherapy regimens for small cell lung cancer at various stages of the disease was carried out, presented in 408 case histories of patients who were treated from January 2021 to December 2021 in oncological dispensaries of the Voronezh and Lipetsk regions. During the study, the main regimens used in chemotherapy were identified and the most expensive treatment regimen for small cell lung cancer was determined, for which 50-70% of the budget is spent this is the scheme: etoposide + carboplatin and the least expensive group of drugs, for which 5-10% of the budget is spent this is scheme 3: cyclophosphamide 1000 mg/m2 in the 1st day + doxorubicin 50 mg/m2 on day 1 + vincristine 1.5 mg/m2 on day 1.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
